Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: A real-life registry study in Japan (the ACTRA-RI study)

Annals of the Rheumatic Diseases

Volumn 74, Issue 3, 2015, Pages 627-630

  Mori, Shunsuke ^a   Yoshitama, Tamami ^b   Hidaka, Toshihiko ^c   Hirakata, Naoyuki ^d   Ueki, Yukitaka ^a  

^a NHO Kumamoto Saishunsou National Hospital   (Japan)

^b Yoshitama Clinic for Rheumatic Diseases   (Japan)

^c Zenjinkai Shimin No Mori Hospital   (Japan)

^d SASEBO CHUO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY FAILURE; LETTER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK FACTOR; UNSPECIFIED SIDE EFFECT; AGED; ARTHRITIS, RHEUMATOID; CHRONIC KIDNEY FAILURE; COMPLICATION; JAPAN; MIDDLE AGED; REGISTER; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; REGISTRIES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84922373649     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206695     Document Type: Letter

References (10)

1. Karie S, Gandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 2008;47:350-4.
2. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013;72:1897-904.
3. Verstappen SM, Bakker MF, Heurkens AH, et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis 2010;69:1044-8.
4. Ng B, Chu A. Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis. Clin Rheumatol 2014;33:21-30.
5. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92.
6. Redal-Baigorri B, Rasmussen K, Heaf JG. Indexing glomerular filtration rate to body surface area: clinical consequences. J Clin Lab Anal 2014;28:83-90.
7. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
8. Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014;73:803-9.
9. Fassett RG. Current and emerging treatment options for the elderly patient with chronic kidney disease. Clin Interv Aging 2014;9:191-9.
10. Anders HJ, Vielhauer V. Renal co-morbidity in patients with rheumatic diseases. Arthritis Res Ther 2011;13:222.